Northland Capmk Forecasts MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Investment analysts at Northland Capmk issued their Q1 2026 earnings per share (EPS) estimates for shares of MiMedx Group in a research report issued on Tuesday, January 20th. Northland Capmk analyst C. Byrnes anticipates that the company will post earnings of $0.02 per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.12 EPS.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The firm had revenue of $113.73 million during the quarter, compared to analyst estimates of $94.74 million.

Other analysts have also issued reports about the stock. Lake Street Capital dropped their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho cut their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

MiMedx Group Trading Down 0.6%

Shares of MDXG opened at $5.39 on Wednesday. The stock has a market capitalization of $798.26 million, a P/E ratio of 19.96 and a beta of 1.57. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The firm has a fifty day simple moving average of $6.70 and a two-hundred day simple moving average of $6.90. MiMedx Group has a twelve month low of $5.13 and a twelve month high of $9.36.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC boosted its stake in MiMedx Group by 63.8% during the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after acquiring an additional 7,107 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of MiMedx Group during the third quarter valued at approximately $54,000. Headlands Technologies LLC bought a new position in MiMedx Group during the second quarter valued at approximately $72,000. Finally, Osaic Holdings Inc. lifted its position in MiMedx Group by 57.2% during the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock valued at $79,000 after purchasing an additional 4,708 shares during the period. Institutional investors own 79.15% of the company’s stock.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total transaction of $432,586.00. Following the completion of the transaction, the insider directly owned 236,982 shares in the company, valued at $1,758,406.44. This trade represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.